PDCD1 and hepatitis A virus infection: Second-line immunosuppressive therapy was given in 9% of the patients with PD-1 inhibitor-induced hepatitis, in 20% of the patients with ipilimumab induced hepatitis and in 24% of the patients with combination therapy induced hepatitis (p = 0.29).